The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myelomaAndrew Spencer, Christine Chen, Deborah A. Smith et al.|Blood|2014Cited by 140
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancersPeter Sabbatini, Rakesh Kumar|Molecular Cancer Therapeutics|2009Cited by 98
Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine KinasePeter Sabbatini, Rakesh Kumar|Clinical Cancer Research|2009Cited by 79
Identification of Pax5 as a Target of MTA1 in B-Cell LymphomasSeetharaman Balasenthil, Rakesh Kumar, Anupama E. Gururaj et al.|Cancer Research|2007Cited by 68
Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora APoonam R. Molli, Rakesh Kumar|The Journal of Cell Biology|2010Cited by 59